Trials / Completed
CompletedNCT01249261
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numbers)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Warner Chilcott · Industry
- Sex
- Female
- Age
- 85 Years
- Healthy volunteers
- Not accepted
Summary
The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risedronate | 5 mg/day |
| DRUG | Placebo/Risedronate | placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8 |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2003-05-01
- Completion
- 2003-05-01
- First posted
- 2010-11-29
- Last updated
- 2011-11-02
- Results posted
- 2011-10-26
Locations
13 sites across 8 countries: Australia, Belgium, Denmark, Finland, Italy, Poland, Spain, Sweden
Source: ClinicalTrials.gov record NCT01249261. Inclusion in this directory is not an endorsement.